Home
Companies
Catalysts
Deep Dives
Chronic kidney disease
CKD · CVRM · 2 drugs · 2 indications
Progressive loss of kidney function over time.
Competitive Landscape (2 drugs)
Drug
Company
Mechanism
Modality
Route
Stage
Jardiance
LLY
SGLT2 inhibitor
Small molecule
ORAL
APPROVED
Farxiga
AZN
SGLT2 inhibitor
Small molecule
ORAL
APPROVED
Indications (2)
Chronic kidney disease
Farxiga
APPROVED
CKD
Jardiance
APPROVED
Data from Supabase · Updated 2026-03-24